2023 World Conference on Lung Cancer (Posters)-EP08.02. Long-Term Efficacy and Safety of Tislelizumab Plus Chemotherapy as Neoadjuvant/Adjuvant Therapy for IIB-III NSCLC: A Retrospective Study

EP08.02. Long-Term Efficacy and Safety of Tislelizumab Plus Chemotherapy as Neoadjuvant/Adjuvant Therapy for IIB-III NSCLC: A Retrospective Study - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the long-term efficacy and safety of using neoadjuvant and adjuvant tislelizumab in combination with chemotherapy for resectable stage IIB-III non-small cell lung cancer (NSCLC). The study included 23 patients who received neoadjuvant tislelizumab combined with chemotherapy followed by adjuvant tislelizumab therapy. The primary endpoint was the 2-year event-free survival (EFS) rate.<br /><br />The results showed that the 2-year EFS rate was 76.2%, with a median EFS that did not arrive. The objective response rate (ORR) was 85%, and the complete response (CR) rate was 5%. The surgery rate was 95.65%, with a 100% R0 resection rate. The down-staging rate was 90.9%. The major pathological response (MPR) was 72.7%, and the pathological complete response (pCR) was 36.4%.<br /><br />Patients with pCR had a higher 2-year EFS rate compared to patients without pCR. The study also found that the combination therapy was associated with tolerable adverse events, including pruritus, dermatitis, and myelosuppression.<br /><br />In conclusion, neoadjuvant and adjuvant tislelizumab combined with chemotherapy showed long-term EFS benefit and tolerable adverse events in patients with resectable stage IIB-III NSCLC in a real-world setting. These findings suggest that this treatment approach may be effective and safe for this patient population. Further research and larger studies are needed to validate these results.

Asset Subtitle

Yang Cheng

Meta Tag

Speaker Yang Cheng

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

neoadjuvant tislelizumab

adjuvant tislelizumab

chemotherapy

resectable stage IIB-III NSCLC

long-term efficacy

safety

2-year event-free survival rate

objective response rate

complete response rate

surgery rate